





Case 21374YP

In the Claims:

1(Original). A compound represented by Formula (I), (II), (III) or (IV):




or



or a pharmaceutically acceptable salt thereof, wherein

Case 21374YP


HET is one of the following heterocycles:

 R^1 is

- (a) H;
- (b) C_1 - C_6 -alkyl, C_2 - C_4 -alkenyl, C_2 - C_4 -alkynyl, C_3 - C_6 -cycloalkyl, or C_1 - C_4 -alkyl- $[C_3$ - C_6 -cycloalkyl], any of which is optionally substituted with one or more of the following substituents: F, CF_3 , OH, O -(C_1 - C_4)alkyl, $S(O)_{0-2}$ -(C_1 - C_4)alkyl, O -CONR^aR^b, NR^aR^b, N(R^a)CONR^aR^b, COO-(C_1 - C_4)alkyl, COOH, CN, CONR^aR^b, SO₂NR^aR^b, N(R^a)SO₂NR^aR^b, -C(=NH)NH₂, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;
- (c) -O- C_1 - C_6 -alkyl, -O- C_3 - C_6 -cycloalkyl, -S- C_1 - C_6 -alkyl or -S- C_3 - C_6 -cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF_3 , OH, O -(C_1 - C_4)alkyl, $S(O)_{0-2}$ -(C_1 - C_4)alkyl, O -CONR^aR^b, NR^aR^b, N(R^a)CONR^aR^b, COO-(C_1 - C_4)alkyl, COOH, CN, CONR^aR^b, SO₂NR^aR^b, N(R^a)SO₂NR^aR^b, -C(=NH)NH₂, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;
- (d) - C_0 - C_4 -alkyl- C_1 - C_4 -perfluoroalkyl, or -O- C_0 - C_4 -alkyl- C_1 - C_4 -perfluoroalkyl;
- (e) -OH;
- (f) -O-aryl, or -O- C_1 - C_4 -alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) - C_0 -4alkyl-CO-OR^a, viii) -(C_0 -4alkyl)-NH-CO-OR^a, ix) -(C_0 -4alkyl)-CO-N(R^a)(R^b), x) -S(O)₀₋₂R^a, xi) -SO₂N(R^a)(R^b), xii) -NR^aSO₂R^a, xiii) - C_1 -10alkyl, and xiv) - C_1 -10alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-;
- (g) -OCON(R^a)(R^b), or -OSO₂N(R^a)(R^b);
- (h) -SH, or -SCON(R^a)(R^b);

Case 21374YP

- (i) NO_2 ;
- (j) NR^aR^b , $-\text{N}(\text{COR}^a)\text{R}^b$, $-\text{N}(\text{SO}_2\text{R}^a)\text{R}^b$, $-\text{N}(\text{R}^a)\text{SO}_2\text{N}(\text{R}^a)_2$, $-\text{N}(\text{OR}^a)\text{CONR}^a\text{R}^b$, $-\text{N}(\text{R}^a)\text{SO}_2\text{R}^a$ or $-\text{N}(\text{R}^a)\text{CON}(\text{R}^a)_2$;
- (k) $-\text{CH}(\text{OR}^a)\text{R}^a$, $-\text{C}(\text{OR}^b)\text{CF}_3$, $-\text{CH}(\text{NHR}^b)\text{R}^a$, $-\text{C}(=\text{O})\text{R}^a$, $\text{C}(=\text{O})\text{CF}_3$, $-\text{SOCH}_3$, $-\text{SO}_2\text{CH}_3$, COOR^a , CN , CONR^aR^b , $-\text{COCONR}^a\text{R}^b$, $-\text{SO}_2\text{NR}^a\text{R}^b$, $-\text{CH}_2\text{O}-\text{SO}_2\text{NR}^a\text{R}^b$, $\text{SO}_2\text{N}(\text{R}^a)\text{OR}^a$, $-\text{C}(=\text{NH})\text{NH}_2$, $-\text{CR}^a=\text{N}-\text{OR}^a$, $\text{CH}=\text{CHCONR}^a\text{R}^b$;
- (l) $-\text{CONR}^a(\text{CH}_2)_{0-2}\text{C}(\text{R}^a)(\text{R}^b)(\text{CH}_2)_{0-2}\text{CONR}^a\text{R}^b$;
- (m) tetrazolyl, tetrazolinonyl, triazolyl, triazolinonyl, imidazolyl, imidazolonyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrazolonyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, or phenyl, any of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) $-\text{CN}$, iii) $-\text{NO}_2$, iv) $-\text{C}(=\text{O})\text{R}^a$, v) C_1 - C_6 -alkyl, vi) $-\text{O}-\text{R}^a$, vii) $-\text{NR}^a\text{R}^b$, viii) $-\text{C}_0$ - C_4 -alkyl $-\text{CO}-\text{O}-\text{R}^a$, ix) $-(\text{C}_0$ - C_4 -alkyl)- $\text{NH}-\text{CO}-\text{OR}^a$, x) $-(\text{C}_0$ - C_4 -alkyl)- $\text{CO}-\text{NR}^a\text{R}^b$, xi) $-\text{S}(\text{O})_{0-2}\text{R}^a$, xii) $-\text{SO}_2\text{NR}^a\text{R}^b$, xiii) $-\text{NH}\text{SO}_2\text{R}^a$, xiv) $-\text{C}_1$ - C_4 -perfluoroalkyl, and xv) $-\text{O}-\text{C}_1$ - C_4 -perfluoroalkyl;
- (n) $-\text{C}(\text{R}^a)=\text{C}(\text{R}^b)-\text{COOR}^a$, or $-\text{C}(\text{R}^a)=\text{C}(\text{R}^b)-\text{CONR}^a\text{R}^b$;
- (o)



- (p) piperidin-1-yl, morpholin-1-yl, pyrrolidin-1-yl, piperazin-1-yl or 4-substituted piperazin-1-yl, any of which is optionally substituted with 1-3 substituents selected from i) $-\text{CN}$, ii) $-\text{C}(=\text{O})(\text{R}^a)$, iii) C_1 - C_6 -alkyl, iv) $-\text{OR}^a$, v) $-\text{NR}^a\text{R}^b$, vi) $-\text{C}_0$ - C_4 -alkyl $-\text{CO}-\text{OR}^a$, vii) $-(\text{C}_0$ - C_4 -alkyl)- $\text{NH}-\text{CO}-\text{OR}^a$, viii) $-(\text{C}_0$ - C_4 -alkyl)- $\text{CON}(\text{R}^a)(\text{R}^b)$, ix) $-\text{SR}^a$, x) $-\text{S}(\text{O})_{0-2}\text{R}^a$, xi) $-\text{SO}_2\text{N}(\text{R}^a)(\text{R}^b)$, xii) $-\text{NR}^a\text{SO}_2\text{R}^a$, xiii) $-\text{C}_1$ - C_4 -perfluoroalkyl and xiv) $-\text{O}-\text{C}_1$ - C_4 -perfluoroalkyl;

R^a is

- (a) H;
- (b) C_1 - C_4 -alkyl, optionally substituted with one or more of the following substituents: F, CF_3 , OH, $\text{O}-(\text{C}_1$ - C_4)alkyl, $\text{S}(\text{O})_{0-2}-(\text{C}_1$ - C_4)alkyl, $-\text{OCONH}_2$, $-\text{OCONH}(\text{C}_1$ - C_4)alkyl, $-\text{OCON}(\text{C}_1$ - C_4)alkyl, $-\text{OCONHC}_1$ - C_4 alkyl-aryl, $-\text{OCON}(\text{C}_1$ - C_4)alkyl, NH_2 , $\text{NH}(\text{C}_1$ - C_4)alkyl, $\text{N}(\text{C}_1$ - C_4)alkyl, $\text{NH}(\text{C}_1$ - C_4)alkyl-aryl, $\text{N}(\text{C}_1$ - C_4)alkyl, NHCONH_2 , $\text{NHCONH}(\text{C}_1$ - C_4)alkyl, $\text{NHCONH}(\text{C}_1$ - C_4)alkyl-aryl, $-\text{NHCON}(\text{C}_1$ - C_4)alkyl, $\text{NHCON}(\text{C}_1$ -

Case 21374YP

C₄alkyl)(C₁-C₄alkyl-aryl), N(C₁-C₄alkyl)CON(C₁-C₄alkyl)(C₁-C₄alkyl), N(C₁-C₄alkyl)CON(C₁-C₄alkyl)(C₁-C₄alkyl-aryl), COO-(C₁-C₄alkyl), COOH, CN, CONH₂, CONH(C₁-C₄alkyl), CON(C₁-C₄alkyl)(C₁-C₄alkyl), SO₂NH₂, SO₂NH(C₁-C₄alkyl), SO₂NH(C₁-C₄alkyl-aryl), SO₂N(C₁-C₄alkyl)(C₁-C₄alkyl), NHSO₂NH₂, -C(=NH)NH₂, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;

(c) C₀-C₄-alkyl-(C₁-C₄)-perfluoroalkyl; or

(d) -C₁-C₄-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)(C₁-C₄-alkyl), v) -O(C₁-C₄-alkyl), vi) -N(C₁-C₄-alkyl)(C₁-C₄-alkyl), vii) -C₁-10alkyl, and viii) -C₁-10alkyl, wherein one or more of the alkyl carbons can be replaced by a -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-;

R^b is

(a) H; or

(b) C₁-C₆-alkyl, optionally substituted with one or more of the following substituents: F, CF₃, OH, O-(C₁-C₄)alkyl, S(O)₀₋₂-(C₁-C₄)alkyl, -OCONH₂, -OCONH(C₁-C₄alkyl), NH₂, NH(C₁-C₄alkyl), N(C₁-C₄alkyl)(C₁-C₄alkyl), NHCONH₂, NHCONH(C₁-C₄alkyl), -NHCON(C₁-C₄alkyl)(C₁-C₄alkyl), COO-(C₁-C₄-alkyl), COOH, CN, or CONH₂;

R² is:

(a) H;

(b) -C₁-C₄-alkyl, -C₃-C₆-cycloalkyl or -C₁-C₄-alkyl-(C₃-C₆)-cycloalkyl, optionally substituted with one or more of the following substituents: F, CF₃, OH, O-(C₁-C₄)alkyl, S(O)₀₋₂-(C₁-C₄)alkyl, O-CONR^aR^b, NR^aR^b, N(R^a)CONR^aR^b, COO-(C₁-C₄)alkyl, COOH, CN, CONR^aR^b, SO₂NR^aR^b, N(R^a)SO₂NR^aR^b, -C(=NH)NH₂, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;

(c) -C₀-C₄-alkyl-C₁-C₄-perfluoroalkyl;

(d) aryl or -(C₁-C₄-alkyl)-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I,

Case 21374YP

- ii) -CN, iii) -NO₂, iv) -C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C₀₋₄alkyl-CO-OR^a, viii) -(C₀₋₄alkyl)-NH-CO-OR^a, ix) -(C₀₋₄alkyl)-CO-N(R^a)(R^b), x) -S(O)₀₋₂R^a, xi) -SO₂N(R^a)(R^b), xii) -NR^aSO₂R^a, xiii) -C₁₋₁₀alkyl, and xiv) -C₁₋₁₀alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-;
- (e) -C(=O)(R^a), -CONR^aR^b, COO-(C₁₋₄)alkyl, -SO₂R^a, N(R^a)COR^a, -SO₂N(R^a)(R^b);

R³ is

- (a) H;
- (b) -C₁₋₄-alkyl, -C₃₋₆-cycloalkyl or -C₁₋₄-alkyl-(C₃₋₆)-cycloalkyl, optionally substituted with one or more of the following substituents: F, CF₃, OH, O-(C₁₋₄)alkyl, S(O)₀₋₂-(C₁₋₄)alkyl, O-CONR^aR^b, NR^aR^b, N(R^a)CONR^aR^b, COO-(C₁₋₄)alkyl, COOH, CN, CONR^aR^b, SO₂NR^aR^b, N(R^a)SO₂NR^aR^b, -C(=NH)NH₂, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;
- (c) -C₀₋₄-alkyl-C₁₋₄-perfluoroalkyl;
- (d) aryl or -(C₁₋₄-alkyl)-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C₀₋₄alkyl-CO-OR^a, viii) -(C₀₋₄alkyl)-NH-CO-OR^a, ix) -(C₀₋₄alkyl)-CO-N(R^a)(R^b), x) -S(O)₀₋₂R^a, xi) -SO₂N(R^a)(R^b), xii) -NR^aSO₂R^a, xiii) -C₁₋₁₀alkyl, and xiv) -C₁₋₁₀alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-;
- (e) -O-C₁₋₄-alkyl, -O-C₀₋₄-alkyl-C₁₋₄-perfluoroalkyl, -O-aryl or -O(C₁₋₄-alkyl)-aryl;
- (f) -C(=O)(R^a), -SO₂R^a, -SO₂N(R^a)(R^b), CN, NR^aR^b, NO₂, F, Cl, Br, I, OH, OCONR^aR^b, O(C₁₋₄-alkyl)CONR^aR^b, -OSO₂NR^aR^b, COOR^a, N(R^a)COR^a, or CONR^aR^b;

R⁴ and R⁵ each independently is:

- (a) H;

Case 21374YP

- (b) -C₁-C₆-alkyl, -C₂-C₆-alkenyl, -C₂-C₆-alkynyl or -C₃-C₆-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF₃, -O-(C₁-C₄)alkyl, CN, -N(R^a)(R^b), -N(R^a)CO-(C₁-C₄)alkyl, COOR^b, CON(R^a)(R^b) or phenyl;
- (c) -O-C₀-C₆-alkyl, -O-aryl, or -O-C₁-C₄-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C₀₋₄alkyl-CO-OR^a, viii) -(C₀₋₄alkyl)-NH-CO-OR^a, ix) -(C₀₋₄alkyl)-CO-N(R^a)(R^b), x) -S(O)₀₋₂R^a, xi) -SO₂N(R^a)(R^b), xii) -NR^aSO₂R^a, xiii) -C₁₋₁₀alkyl, and xiv) -C₁₋₁₀alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-;
- (d) -C₀-C₄-alkyl-C₁-C₄-perfluoroalkyl, or -O-C₀-C₄-alkyl-C₁-C₄-perfluoroalkyl; or
- (e) CN, NH₂, NO₂, F, Cl, Br, I, OH, OCON(R^a)(R^b) O(C₁-C₄-alkyl)CONR^aR^b, -OSO₂N(R^a)(R^b), COOR^b, CON(R^a)(R^b), or aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C₀₋₄alkyl-CO-OR^a, viii) -(C₀₋₄alkyl)-NH-CO-OR^a, ix) -(C₀₋₄alkyl)-CO-N(R^a)(R^b), x) -S(O)₀₋₂R^a, xi) -SO₂N(R^a)(R^b), xii) -NR^aSO₂R^a, xiii) -C₁₋₁₀alkyl, and xiv) -C₁₋₁₀alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-; and

R⁶, R⁷ and R⁸ each independently is:

- (a) H;
- (b) C₁-C₆-alkyl, C₂-C₄-alkenyl, C₂-C₄-alkynyl or C₃-C₆-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF₃, OH, O-(C₁-C₄)alkyl, OCON(R^a)(R^b), NR^aR^b, COOR^a, CN, CONR^aR^b, N(R^a)CONR^aR^b, N(R^a)SO₂NR^aR^b, SO₂NR^aR^b, S(O)₀₋₂(C₁-C₄-alkyl), -C(=NH)NH₂, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl, or piperazinyl;
- (c) -O-C₁-C₆-alkyl, -O-C₃-C₆-cycloalkyl, -S-C₁-C₆-alkyl or -S-C₃-C₆-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF₃, OH, O-(C₁-C₄)alkyl, NH₂, NH(C₁-C₄-alkyl), N(C₁-C₄-alkyl)₂, COOH, CN, CONH₂,

Case 21374YP

CONH(C₁-C₄-alkyl), CONH(C₁-C₄-alkyl)₂, SO₂NH₂, SO₂NH(C₁-C₄-alkyl), tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl, or piperazinyl;

- (d) -C₀-C₄-alkyl-C₁-C₄-perfluoroalkyl, or -O-C₀-C₄-alkyl-C₁-C₄-perfluoroalkyl;
- (e) -O-aryl, or -O-C₁-C₄-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C₀₋₄alkyl-CO-OR^a, viii) -(C₀₋₄alkyl)-NH-CO-OR^a, ix) -(C₀₋₄alkyl)-CO-N(R^a)(R^b), x) -S(O)₀₋₂R^a, xi) -SO₂N(R^a)(R^b), xii) -NR^aSO₂R^a, xiii) -C₁₋₁₀alkyl, and xiv) -C₁₋₁₀alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C; (f) CN, N(R^a)(R^b), NO₂, F, Cl, Br, I, -OR^a, -SR^a, -OCON(R^a)(R^b), -OSO₂N(R^a)(R^b), COOR^b, CON(R^a)(R^b), -N(R^a)CON(R^a)(R^b), -N(R^a)SO₂N(R^a)(R^b), -C(OR^b)R^a, -C(OR^a)CF₃, -C(NHR^a)CF₃, -C(=O)R^a, C(=O)CF₃, -SOCH₃, -SO₂CH₃, -NHSO₂(C₁₋₆-alkyl), -NHSO₂-aryl, SO₂N(R^a)(R^b), -CH₂OSO₂N(R^a)(R^b), SO₂N(R^b)-OR^a, -C(=NH)NH₂, -CR_a=N-OR_a, CH=CH or aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C₀₋₄alkyl-CO-OR^a, viii) -(C₀₋₄alkyl)-NH-CO-OR^a, ix) -(C₀₋₄alkyl)-CO-N(R^a)(R^b), x) -S(O)₀₋₂R^a, xi) -SO₂N(R^a)(R^b), xii) -NR^aSO₂R^a, xiii) -C₁₋₁₀alkyl, and xiv) -C₁₋₁₀alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C; or when R⁶ and R⁷ are present on adjacent carbon atoms, R⁶ and R⁷, together with the ring to which they are attached, may form a bicyclic aromatic ring selected from naphthyl, indolyl, quinolinyl, isoquinolinyl, quinoxalinyl, benzofuryl, benzothienyl, benzoxazolyl, benzothiazolyl, and benzimidazolyl, any aromatic ring of which is optionally substituted with 1-4 independent substituents selected from i) halogen, ii) -CN, iii) -NO₂, iv) -CHO, v) -O-C₁₋₄alkyl, vi) -N(C₀₋₄alkyl)(C₀₋₄alkyl), vii) -C₀₋₄alkyl-CO-O(C₀₋₄alkyl), viii) -(C₀₋₄alkyl)-NH-CO-O(C₀₋₄alkyl), ix) -(C₀₋₄alkyl)-CO-N(C₀₋₄alkyl)(C₀₋₄alkyl), x) -S(C₀₋₄alkyl), xi) -S(O)(C₁₋₄alkyl), xii) -SO₂(C₀₋₄alkyl), xiii) -SO₂N(C₀₋₄alkyl)(C₀₋₄alkyl), xiv) -NHSO₂(C₀₋₄alkyl)(C₀₋₄alkyl), xv) -C₁₋₁₀alkyl and xvi) -C₁₋₁₀alkyl in which one

Case 21374YP

or more of the carbons can be replaced by a -N(C₀₋₆alkyl)-, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-N(C₀₋₆alkyl)-, -N(C₀₋₆alkyl)-C(O)-, -N(C₀₋₆alkyl)-C(O)-N(C₀₋₆alkyl)-, -C(O)-, -CH(OH), -C=C-, or -C≡C-; with the proviso that R¹, R³ and R⁶ are not hydrogen at the same time.

2(Original). The compound according to Claim 1 represented by Formula (I), or a pharmaceutically acceptable salt thereof.

3(Original). The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

R⁶ is other than H and is attached at the ortho position.

4(Original). The compound according to Claim 1 represented by Formula (II), or a pharmaceutically acceptable salt thereof.


5(Original). The compound according to Claim 4, or a pharmaceutically acceptable salt thereof, wherein

R⁶ is other than H and is attached at the ortho position.

6(Original). The compound according to Claim 1 represented by Formula (III), or a pharmaceutically acceptable salt thereof.


7(Original). The compound according to Claim 6, or a pharmaceutically acceptable salt thereof, wherein

HET is



8(Original). The compound according to Claim 6, or a pharmaceutically acceptable salt thereof, wherein

HET is




9(Original). The compound according to Claim 6, or a pharmaceutically acceptable salt thereof, wherein

HET is




10(Original). The compound according to Claim 6 or a pharmaceutically acceptable salt thereof, wherein

HET is



11(Original). The compound according to Claim 6, or a pharmaceutically acceptable salt thereof, wherein

HET is



Case 21374YP


12(Original). The compound according to Claim 6, or a pharmaceutically acceptable salt thereof, wherein

R^6 is other than H and is attached at the ortho position.

13(Original). The compound according to Claim 1 represented by Formula (IV), or a pharmaceutically acceptable salt thereof.


14(Original). The compound according to Claim 13, or a pharmaceutically acceptable salt thereof, wherein

HET is




15(Original). The compound according to Claim 13, or a pharmaceutically acceptable salt thereof, wherein

HET is



16(Original). The compound according to Claim 13, or a pharmaceutically acceptable salt thereof, wherein


HET is



17(Original). The compound according to Claim 13, or a pharmaceutically acceptable salt thereof, wherein


Case 21374YP

HET is



18(Original). The compound according to Claim 13, or a pharmaceutically acceptable salt thereof, wherein

HET is




19(Original). The compound according to Claim 13, or a pharmaceutically acceptable salt thereof, wherein

R⁶ is other than H and is attached at the ortho position.


Case 21374YP

20(Original). A compound represented by



or a pharmaceutically acceptable salt thereof.




21(Currently Amended). The compound according to Claim 1 represented by



as indicated by the compound number herein:

Compd	R ⁸	R ⁷	R ⁶	R ⁴	R ³	R ¹
1	H	H	CF ₃	H	H	CH ₃
2	H	H	OCF ₃	H	H	CH ₃
3	H	H	OCF ₃	H	CH ₃	H
4	H	H	CF ₃	H	CH ₃	H
5	H	H	CF ₃	H	CH ₃	CH ₃
6	H	H	OCF ₃	H	CH ₃	CH ₃
7	H	H	Cl	H	H	CF ₃
8	H	H	Cl	H	CH ₃	CONH ₂
9	H	H	CF ₃	H	CH ₃	CONH ₂
10	H	H	CF ₃	H	CH ₃	COOCH ₃
11	H	H	CF ₃	H	CH ₃	COOH
12	H	H	Cl	H	t-Bu	COOH
13	H	H	OCF ₃	H	CH ₃	COOCH ₃
14	H	H	OCF ₃	H	CH ₃	CONH ₂
15	H	H	OCF ₃	H	CH ₃	COOH
16	H	H	OCF ₃	H	COOEt	CH ₃

Case 21374YP


17	H	H	CF ₃	H	COOEt	CH ₃
18	H	H	OCF ₃	H	COOH	CH ₃
19	H	H	CF ₃	H	COOH	CH ₃
20	H	H	OH	H	CH ₃	CONH ₂
21	H	H	O-Ph	H	CH ₃	COOH
22	H	H	O-Ph	H	CH ₃	COOMe
23	H	H	O-Ph	H	CH ₃	COOEt
24	H	H	O-Ph	H	CH ₃	CONH ₂
25	H	H	CHO	H	CH ₃	CONH ₂
26	H	4-Cl	Cl	H	CH ₃	CONH ₂
27	H	4-CF ₃	H	H	CH ₃	CONH ₂
28	H	3-CF ₃	H	H	CH ₃	CONH ₂
29	5-Cl	3-Cl	H	H	CH ₃	CONH ₂
30	H	3-F	H	H	CH ₃	CONH ₂
31	5-CF ₃	3-CF ₃	H	H	CH ₃	CONH ₂
32	4-F	3-Cl	H	H	CH ₃	CONH ₂
33	H	4-Cl	H	H	CH ₃	CONH ₂
34	H	4-F	H	H	CH ₃	CONH ₂
35	4-Cl	3-Cl	H	H	CH ₃	CONH ₂
36	H	3-OCH ₃	OCH ₃	H	CH ₃	CONH ₂
37	H	3-Cl	CH ₃	H	CH ₃	CONH ₂
38	H	5-Cl	OCH ₃	H	CH ₃	CONH ₂
39	H	H		H	CH ₃	CONH ₂
40	H	3- 	H	H	CH ₃	CONH ₂
41	H	3-Ph	H	H	CH ₃	CONH ₂
42	H	H		H	CH ₃	CONH ₂
43	H	4-CH ₂ OH	H	H	CH ₃	CONH ₂
44	H	H	H	H	CH ₃	CONH ₂
45	H	H	CH ₃	H	CH ₃	CONH ₂
46	H	3-COOH	CH ₃	H	CH ₃	CONH ₂
47	H	3-F	CH ₃	H	CH ₃	CONH ₂
48	H	4-OPh	H	H	CH ₃	CONH ₂
49	H	3-Cl	H	H	CH ₃	CONH ₂
50	H	3-OEt	H	H	CH ₃	CONH ₂
51	H	H	F	H	CH ₃	CONH ₂
52	H	4-OEt	H	H	CH ₃	CONH ₂
53	H	6-F	F	H	CH ₃	CONH ₂
54	H	6-CH ₃	CH ₃	H	CH ₃	CONH ₂
55	H	4-t-Bu	H	H	CH ₃	CONH ₂
56	H	4-OCF ₃	H	H	CH ₃	CONH ₂
57	H	4-COCH ₃	H	H	CH ₃	CONH ₂
58	H	3-COCH ₃	H	H	CH ₃	CONH ₂

59	H	3-CH ₃	CH ₃	H	CH ₃	CONH ₂
60	H	4-COOH	H	H	CH ₃	CONH ₂
61	H	4-CHO	H	H	CH ₃	CONH ₂
62	H	4-CF ₃	CF ₃	H	CH ₃	CONH ₂
63	H	6-CF ₃	CF ₃	H	CH ₃	CONH ₂
64	H	6-F	CF ₃	H	CH ₃	CONH ₂
65	H	5-F	CF ₃	H	CH ₃	CONH ₂
66	H	4-Cl	CF ₃	H	CH ₃	CONH ₂
67	H	3-Cl	Cl	H	CH ₃	CONH ₂
68	H	H	OCH ₂ CF ₃	H	CH ₃	CONH ₂
69	H	H	OCF ₃	F	CH ₃	COOEt
70	H	H	OCF ₃	F	CH ₃	CONH ₂
71	H	H	OCF ₃	F	COOEt	CH ₃
72	H	H	OCF ₃	F	CONH ₂	CH ₃
73	H	3-Cl	Cl	F	CH ₃	CONH ₂
74	H	4-CF ₃	CF ₃	F	CH ₃	CONH ₂
75	H	H	OCF ₃	F	CH ₃	COOH
76	H	5-F	OH	H	CH ₃	CONH ₂
77	H	5-NMe ₂	OCF ₃	H	CH ₃	CONH ₂
78	H	4-F	CF ₃	H	CH ₃	COOH
79	H	4-CF ₃	CF ₃	H	CH ₃	COOH
80	H	4-CF ₃	F	H	CH ₃	COOH
81	H	3-CF ₃	CF ₃	H	CH ₃	COOH
82	H	H	OCF ₃	H	CH ₃	CF ₃
83	H	H	OCF ₃	H	t-Bu	CONH ₂
84	H	H	OCF ₃	H	OCH ₂ CH ₃	CH ₃
85	H	5-F	CF ₃	H	CH ₃	COOH
86	H	3-Cl	Cl	H	CH ₃	COOH
87	H	4-Cl	CF ₃	H	CH ₃	COOH
88	H	3-Cl	Cl	F	CH ₃	COOH
89	H	6-Cl	Cl	H	CH ₃	COOH
90	H	6-Cl	Cl	H	CH ₃	CONH ₂
91	H	6-F	CF ₃	H	CH ₃	COOH
92	H	H	CF ₃	H	CH ₃	COOH
93	H	6-CF ₃	CF ₃	H	CH ₃	COOH
94	H	6-Cl	CF ₃	H	CH ₃	CONH ₂

or a pharmaceutically acceptable salt thereof.



22(Currently Amended). The compound of Claim 1

represented by




as represented by the compound number below:

Case 21374YP

Compd	R ⁶	R ³	R ²	R ¹
<u>1</u>	Cl	H	CONH-t-Bu	H
<u>2</u>	Cl	H	CONH-Me	H
<u>3</u>	Cl	H		H
<u>4</u>	Cl	H		H
<u>5</u>	CF ₃	H	COOEt	NH ₂
<u>6</u>	CF ₃	H	COOH	H
<u>7</u>	OCF ₃	H	COOEt	H
<u>8</u>	OCF ₃	H	COOH	NH ₂

or a pharmaceutically acceptable salt thereof.


23(Original). A compound represented by



or a pharmaceutically acceptable salt thereof.

Case 21374YP



















24(Original). A compound represented by



or a pharmaceutically acceptable salt thereof.


Case 21374YP

25(Original). A compound represented by

or a pharmaceutically acceptable salt thereof.

26(Currently amended). The compound of Claim 1 is represented by












as represented by the compound number below:

Compound	R ^a	R ^b
<u>1</u>	-CH ₂ CH ₂ OH	H
<u>2</u>	-CH ₂ CH ₂ CH ₂ OH	H
<u>3</u>	-CH(CH ₂ OH) ₂	H
<u>4</u>	-CH ₃	H
<u>5</u>	-CH ₂ CH ₃	H
<u>6</u>		H
<u>7</u>		H
<u>8</u>		H
<u>9</u>		H
<u>10</u>		H
<u>11</u>		CH ₃
<u>12</u>		CH ₃
<u>13</u>		H


or a pharmaceutically acceptable salt thereof.

Case 21374YP

27(Original). A compound represented by




Case 21374YP



or a pharmaceutically acceptable salt thereof.

28(Currently Amended). The compound of Claim 1 represented by



as represented by the compound number below:

<u>Compd</u>	<u>R⁷</u>	<u>R⁶</u>	<u>R⁴</u>	<u>R³</u>	<u>R²</u>	<u>R¹</u>
<u>1</u>	H	CF ₃	H	CONH ₂	H	CONH ₂
<u>2</u>	H	OCF ₃	H	CONH ₂	H	CONH ₂
<u>3</u>	4-CF ₃	CF ₃	H	CONH ₂	H	CONH ₂
<u>4</u>	5-F	CF ₃	H	CONH ₂	H	CONH ₂
<u>5</u>	5-CF ₃	OCF ₃	H	CONH ₂	H	CONH ₂
<u>6</u>	H	OCHF ₂	H	CONH ₂	H	CONH ₂
<u>7</u>	5-CF ₃	CF ₃	H	CONH ₂	H	CONH ₂
<u>8</u>	6-F	CF ₃	H	CONH ₂	H	CONH ₂
<u>9</u>	4-F	OCH ₂ CF ₃ CF ₃	H	CONH ₂	H	CONH ₂

Case 21374YP


<u>10</u>	6-CF ₃	CF ₃	H	CONH ₂	H	CONH ₂
<u>11</u>	H	OCH(CH ₃) ₂	H	CONH ₂	H	CONH ₂
<u>12</u>	3-OCF ₃	OCH ₂ CF ₃ CF ₃	H	CONH ₂	H	CONH ₂
<u>13</u>	3-CF ₃	OCH ₂ CF ₃ CF ₃	H	CONH ₂	H	CONH ₂
<u>14</u>	5-F	OCH ₂ CF ₃ CF ₃	H	CONH ₂	H	CONH ₂
<u>15</u>	5-F	OCF ₃	H	CONH ₂	H	CONH ₂
<u>16</u>	4-F	CF ₃	H	CONH ₂	H	CONH ₂
<u>17</u>	H	CF ₃	H	CONH-Et	H	CONH-Et
<u>18</u>	H	CF ₃	H	CONH ₂	H	CONH-Et
<u>19</u>	H	OCF ₃	4-F	CONH ₂	H	CONH ₂
<u>20</u>	H	OCF ₃	H	CONH-Et	H	CONH ₂
<u>21</u>	H	OCF ₃	H	COOEt	H	COOEt
<u>22</u>	H	CF ₃	H	COOEt	H	COOEt
<u>23</u>	H	OCF ₃	H	COOEt	H	CONH ₂
<u>24</u>	H	CF ₃	H	COOEt	H	CONH ₂
<u>25</u>	4-CF ₃	CF ₃	H	COOEt	H	CONH ₂
<u>26</u>	4-CF ₃	CF ₃	H	CONH ₂	H	COOEt
<u>27</u>	H	OCF ₃	H	CONH ₂	H	COOEt
<u>28</u>	H	CF ₃	H	CONH ₂	H	COOEt
<u>29</u>	H	OCF ₃	4-F	COOH	H	COOEt
<u>30</u>	H	OCF ₃	4-F	COOH	H	CONH ₂
<u>31</u>	H	OCF ₃	4-F	CONH ₂	H	COOEt
<u>32</u>	H	OCF ₃	H	COOH	H	CONH ₂
<u>33</u>	H	OCF ₃	H	CH ₃	COOMe	COOEt
<u>34</u>	H	OCF ₃	H	CH ₃	COOH	COOH
<u>35</u>	4-CF ₃	CF ₃	H	CH ₃	COOH	COOH
<u>36</u>	H	OCF ₃	H	CH ₃	CONH ₂	CONH ₂
<u>37</u>	4-CF ₃	CF ₃	H	CH ₃	CONH ₂	CONH ₂
<u>38</u>	H	CF ₃	H	CH ₃	COOH	COOH
<u>39</u>	H	CF ₃	H	CH ₃	CONH ₂	CONH ₂
<u>40</u>	5-CF ₃	CF ₃	H	CH ₃	CONH ₂	CONH ₂
<u>41</u>	5-CF ₃	CF ₃	H	CH ₃	COOH	COOH
<u>42</u>	H	CF ₃	4-OCF ₃	CH ₃	COOMe	COOH
<u>43</u>	H	OCF ₃	4-OCF ₃	CH ₃	CONH ₂	CONH ₂

Case 21374YP

<u>44</u>	H	CF ₃	4-OCF ₃	CH ₃	CONH ₂	CONH ₂
<u>45</u>	H	OCF ₃	4-F	CH ₃	COOEt	COOEt
<u>46</u>	H	CF ₃	4-F	CH ₃	COOEt	COOEt
<u>47</u>	H	OCF ₃	4-F	CH ₃	COOEt	CONH ₂
<u>48</u>	H	OCF ₃	4-F	CH ₃	CONH ₂	CONH ₂
<u>49</u>	H	CF ₃	4-F	CH ₃	COOEt	CONH ₂
<u>50</u>	H	CF ₃	4-F	CH ₃	CONH ₂	CONH ₂
<u>51</u>	H	OCF ₃	4-F	CH ₃	COOH	COOH
<u>52</u>	H	Cl	H	H	CONH-Me	H
<u>53</u>	H	Cl	H	H	CONH ₂	CF ₃
<u>54</u>	H	OCF ₃	H	H	COOEt	NH ₂
<u>55</u>	H	CF ₃	H	H	COOEt	NH ₂
<u>56</u>	H	OCF ₃	H	H	COOH	H
<u>57</u>	H	OCF ₃	H	H	COOEt	H
<u>58</u>	4-CF ₃	CF ₃	H	H	COOEt	NH ₂
<u>59</u>	H	OCF ₃	H	H	COOH	NH ₂
<u>60</u>	H	OCF ₃	H	H	CONH ₂	H
<u>61</u>	H	OCF ₃	H	H	CONH ₂	NH ₂
<u>62</u>	H	OCF ₃	H	CH ₃	CONH ₂	CH ₃
<u>63</u>	H	Cl	H	H	CONH ₂	H

or a pharmaceutically acceptable salt thereof.


29(Currently Amended).The compound of Claim 1 represented by



as represented by the compound number below:

<u>Compd</u>	R ⁷	R ⁶	R ⁴	R ³	R ²	R ¹
<u>1</u>	H	OCF ₃	H	H	COOCH ₃	H
<u>2</u>	H	CF ₃	H	NH ₂	CONH ₂	H

Case 21374YP

<u>3</u>	H	OCF ₃	H	NH ₂	COOH	H
<u>4</u>	H	OCF ₃	H	NH ₂	CONH ₂	H
<u>5</u>	H	CF ₃	H	NH ₂	COOH	H
<u>6</u>	H	OCF ₃	H	H	COOEt	H
<u>7</u>	H	CF ₃	H	H	COOEt	H
<u>8</u>	H	CF ₃	H	H	CONH ₂	
<u>9</u>	H	OCF ₃	F	H	COOEt	H
<u>10</u>	H	OCF ₃	F	H	CONH ₂	H
<u>11</u>	H	OCF ₃	H	CH ₃	COOEt	H
<u>12</u>	H	OCF ₃	H	CH ₃	COOH	H
<u>13</u>	H	OCF ₃	H	CH ₃	CONH ₂	H
<u>14</u>	H	CF ₃	H	CH ₃	COOH	H
<u>15</u>	H	CF ₃	H	CH ₃	CONH ₂	H
<u>16</u>	4-CF ₃	CF ₃	H	CH ₃	COOH	H
<u>17</u>	4-CF ₃	CF ₃	H	CH ₃	CONH ₂	H
<u>18</u>	H	OCF ₃	F	H	COOH	H
<u>19</u>	5-CF ₃	CF ₃	H	H	COOH	H
<u>20</u>	5-CF ₃	CF ₃	H	H	CONH ₂	H
<u>21</u>	H	CF ₃	H	CH ₃	CONH ₂	t-Bu
<u>22</u>	H	OCF ₃	H	H	COOH	t-Bu
<u>23</u>	H	OCF ₃	H	H	CONH ₂	t-Bu
<u>24</u>	6-F	CF ₃	H	H	CONH ₂	H
<u>25</u>	6-F	CF ₃	H	H	COOH	H
<u>26</u>	5-F	OCF ₃	H	H	COOH	H
<u>27</u>	5-F	OCF ₃	H	H	CONH ₂	H
<u>28</u>	4-CF ₃	CF ₃	H	H	CONH ₂	H
<u>29</u>	H	OCF ₃	H	H	CONHNMe ₂	H

or a pharmaceutically acceptable salt thereof.

30(Original). A pharmaceutical composition comprising a therapeutically effective amount of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Case 21374YP

31(Original). The pharmaceutical composition according to Claim 27, further comprising a second therapeutic agent selected from the group consisting of: i) opiate agonists, ii) opiate antagonists, iii) calcium channel antagonists, iv) 5HT receptor agonists, v) 5HT receptor antagonists vi) sodium channel antagonists, vii) NMDA receptor agonists, viii) NMDA receptor antagonists, ix) COX-2 selective inhibitors, x) NK1 antagonists, xi) non-steroidal anti-inflammatory drugs, xii) selective serotonin reuptake inhibitors, xiii) selective serotonin and norepinephrine reuptake inhibitors, xiv) tricyclic antidepressant drugs, xv) norepinephrine modulators, xvi) lithium, xvii) valproate, and xviii) neurontin.

- 32. Cancel.
- 33. Cancel.
- 34. Cancel.
- 35. Cancel.
- 36. Cancel.
- 37. Cancel.
- 38. Cancel.
- 39. Cancel.
- 40. Cancel.
- 41. Cancel.
- 42. Cancel.
- 43. Cancel.
- 44. Cancel.